


Listing of Claims:

1-60 (Cancelled).

61 (Currently Amended). A method for transfecting a cell with a nucleic acid molecule comprising contacting said cell with a sphingoid-polyalkylamine conjugate together with said nucleic acid molecule, wherein said sphingoid-polyalkylamine conjugate ~~comprises a sphingoid backbone carrying, via a carbamoyl bond, at least one polyalkylamine has~~ the following formula (I):



wherein

R₁ represents a hydrogen, a branched or linear alkyl, aryl, alkylamine, or a group -C(O)R₅;

R₂ and R₅ represent, independently, a branched or linear C₁₀-C₂₄ alkyl, alkenyl or polyenyl group;

R₃ is hydrogen or a group -C(O)-NR₆R₇, in which R₆ and R₇, being the same or different for R₃ and R₄, represent, independently, a hydrogen, or a saturated or unsaturated branched or linear polyalkylamine, wherein one or more amine units in said polyalkylamine may be a quaternary ammonium, and R₄ is, independently, a group -C(O)-NR₆R₇, wherein at least one

of **R₃** and /or **R₄** comprises said polyalkylamine; or **R₃** and **R₄** form, together with the oxygen atoms to which they are bound, a heterocyclic ring comprising -C(O)-NR₉-[R₈-NR₉]_m-C(O)-, in which
R₈ represents a saturated or unsaturated C₁-C₄ alkyl and **R₉** represents a hydrogen or a polyalkylamine of the formula -[R₈-NR₉]_n-, wherein said **R₉** or each alkylamine unit -R₈NR₉ may be the same or different in said polyalkylamine; and **n** and **m** represent, independently, an integer from 1 to 10; and
W represents a-CH=CH-, -CH₂-CH(OH)- or -CH₂-CH₂- group.

62 (Previously Presented). The method of Claim 61, wherein said nucleic acid is associated with said sphingoid-polyalkylamine conjugate.

63 (Previously Presented). The method of Claim 61, wherein said nucleic acid molecule is a plasmid DNA.

64 (Previously Presented). The method of Claim 61, wherein said nucleic acid molecule is a small interference RNA (siRNA).

65 (Previously Presented). The method of Claim 61, wherein said nucleic acid molecule is an oligodeoxynucleotide (ODN).

66 (Previously Presented). The method of Claim 62, wherein said sphingoid-polyalkylamine conjugate forms lipid assemblies.

67 (Previously Presented). The method of Claim 66, wherein said sphingoid-polyalkylamine conjugate forms vesicles, micelles or a mixture of same.

68 (Previously Presented). The method of Claim 61, wherein the sphingoid backbone is selected from ceramide, dihydroceramide, phytoceramide, dihydrophytoceramide, ceramine, dihydroceramine, phytoceramine, dihydrophytoceramine.

69 (Previously Presented). The method of Claim 61, wherein said sphingoid backbone is a ceramide.

70 (Previously Presented). The method of Claim 61, wherein said one or more polyalkylamine chains are independently selected from spermine, spermidine, a polyalkylamine analog or a combination thereof.

71 (Cancelled).


72 (Currently Amended). The method of Claim 7161, wherein R_1 represents a $-C(O)R_5$ group, R_5 being as defined.

73 (Currently Amended). The method of Claim 7161, wherein said R_2 and R_5 represent, independently, a linear or branched $C_{12}-C_{18}$ alkyl or alkenyl chain.

74 (Currently Amended). The method of Claim 7161, wherein W represents $-CH=CH-$.

75 (Currently Amended). The method of Claim 7161, wherein R_1 represents a $-C(O)R_5$ group; R_5 represents a $C_{12}-C_{18}$ linear or branched alkyl or alkenyl; W represents $-CH=CH-$; R_2

represents a C₁₂-C₁₈ linear or branched alkyl or alkenyl; **R**₃ and **R**₄ represent, independently, a group -C(O)-NR₆R₇, and **R**₃ may also represent a hydrogen, wherein **R**₆ and **R**₇ represent, independently, a hydrogen or a polyalkylamine having the general formula (II):



wherein

R₈ represent a C₁-C₄ alkyl;


R₉ represents a hydrogen or a polyalkylamine branch of formula (II), said R₈ and R₉ may be the same or different for each alkylamine unit, -R₈NR₉-, in the polyalkylamine of formula (II); and

n represents an integer from 3 to 6.

76 (Currently Amended). The method of Claim 7161, wherein R₃ is a hydrogen atom.

77 (Currently Amended). The method of Claim 7161, wherein both R₃ and R₄ represent the same or different polyalkylamine.

78 (Currently Amended). The method of Claim 7161, wherein **R**₁ represents a -C(O)R₅ group; **R**₅ represents a C₁₂-C₁₈ linear or branched alkyl or alkenyl; **W** represents -CH=CH-; **R**₂ represents a C₁₂-C₁₈ linear or branched alkyl or alkenyl; **R**₃ and **R**₄ represent, independently, a group -C(O)-NR₆R₇, wherein **R**₆ and **R**₇ represent, independently, an alkylamine or a polyalkylamine having the general formula (II):



wherein

R₈ represent a C₁-C₄ alkyl;

R₉ represents a hydrogen or a polyalkylamine branch of formula (II), said R₈ and R₉ may be the same or different for each alkylamine unit, -R₈NR₉-, in the polyalkylamine of formula (II); and

n represents an integer from 3 to 6.

79 (Currently Amended). The method of Claim 7161,

wherein **R**₁ represents a -C(O)R₅ group; **R**₅ represents a C₁₂-C₁₈ linear or branched alkyl or alkenyl; **W** represents -CH=CH-; **R**₂ represents a C₁₂-C₁₈ linear or branched alkyl or alkenyl; **R**₃ and **R**₄ form, together with the oxygen atoms to which they are bonded, a heterocyclic ring comprising -C(O)-[NH-R₈]_n-NH-C(O)-,

wherein

R₈ represents a C₁-C₄ alkyl, wherein for each alkylamine unit -NH-R₈-, said R₈ may be the same or different; and

n represents an integer from 3 to 6.

80 (Currently Amended). The method of Claim 7161,


wherein said R₈ is a C₃-C₄ alkyl.

81 (Currently Amended). The method of Claim 7161, wherein said sphingoid-polyalkylamine conjugate is N-palmitoyl D-erythro sphingosyl-1-carbamoyl spermine (CCS).

82 (Previously Presented). The method of Claim 61, wherein said sphingoid-polyalkylamine conjugate associated with the nucleic acid molecule is also associated with a targeting substance.

83 (Canceled).

84 (Withdrawn/Currently Amended). A method for the treatment of a disease or disorder, the method comprises providing a subject in need of said treatment an amount of a sphingoid-polyalkylamine conjugate associated with a nucleic acid molecule, wherein ~~said sphingoid-polyalkylamine conjugate comprises a sphingoid backbone carrying, via a carbamoyl bond, at least one polyalkylamine and the amount of said nucleic acid molecule is effective to achieve a desired biochemical effect once in said target cell and wherein said sphingoid-polyalkylamine conjugate has the following formula (I):~~



wherein

R₁ represents a hydrogen, a branched or linear alkyl, aryl, alkylamine, or a group -C(O)R₅;

R₂ and R₅ represent, independently, a branched or linear C₁₀-C₂₄ alkyl, alkenyl or polyenyl group;

R₃ is hydrogen or a group $-C(O)-NR_6R_7$, in which **R₆** and **R₇**, being the same or different for **R₃** and **R₄**, represent, independently, a hydrogen, or a saturated or unsaturated branched or linear polyalkylamine, wherein one or more amine units in said polyalkylamine may be a quaternary ammonium, and **R₄** is, independently, a group $-C(O)-NR_6R_7$, wherein at least one of **R₃** and /or **R₄** comprises said polyalkylamine; or **R₃** and **R₄** form, together with the oxygen atoms to which they are bound, a heterocyclic ring comprising $-C(O)-NR_9-[R_8-NR_9]_m-C(O)-$, in which **R₈** represents a saturated or unsaturated C_1-C_4 alkyl and **R₉** represents a hydrogen or a polyalkylamine of the formula $-[R_8-NR_9]_n-$, wherein said **R₉** or each alkylamine unit $-R_8NR_9$ may be the same or different in said polyalkylamine; and **n** and **m** represent, independently, an integer from 1 to 10; and

W represents a- $CH=CH-$, $-CH_2-CH(OH)-$ or $-CH_2-CH_2-$ group.

85 (Withdrawn). The method of Claim 84, wherein said sphingoid backbone is ceramide.

86 (Cancelled).


87 (Withdrawn). The method of Claim 84, wherein said sphingoid-polyalkylamine conjugate is N-palmitoyl D-erythro sphingosyl carbamoyl-spermine (CCS).

88 (Withdrawn/Currently Amended). A transfection composition comprising:

a sphingoid-polyalkylamine conjugate comprising a sphingoid backbone carrying, via a carbamoyl bond, at least one polyalkylamine; and

a nucleic acid molecule,

wherein said sphingoid-polyalkylamine conjugate has
the following formula (I):



wherein

R1 represents a hydrogen, a branched or linear alkyl,
aryl, alkylamine, or a group -C(O)R5;

R2 and R5 represent, independently, a branched or
linear C₁₀-C₂₄ alkyl, alkenyl or polyenyl group;

R3 is hydrogen or a group -C(O)-NR₆R₇, in which R₆ and
R₇, being the same or different for R₃ and R₄, represent,
independently, a hydrogen, or a saturated or unsaturated
branched or linear polyalkylamine, wherein one or more amine
units in said polyalkylamine may be a quaternary ammonium, and
R4 is, independently, a group -C(O)-NR₆R₇, wherein at least one
of R₃ and /or R₄ comprises said polyalkylamine; or R₃ and R₄
form, together with the oxygen atoms to which they are bound, a
heterocyclic ring comprising -C(O)-NR₉-[R₈-NR₉]_m-C(O)-, in which

R₈ represents a saturated or unsaturated C₁-C₄ alkyl and R₉ represents a hydrogen or a polyalkylamine of the formula -[R₈-NR₉]_n-, wherein said R₉ or each alkylamine unit -R₈NR₉ may be the same or different in said polyalkylamine; and n and m represent, independently, an integer from 1 to 10; and

W represents a-CH=CH-, -CH₂-CH(OH)- or -CH₂-CH₂- group.

89 (Withdrawn). The transfection composition of Claim 88, comprising a physiologically acceptable carrier.

90 (Withdrawn). The transfection composition of Claim 88, wherein said nucleic acid molecule has, at a physiological pH, a net negative dipole moment, at least one area carrying a negative charge or a net negative charge.

91 (Withdrawn). The transfection composition of Claim 88, wherein said nucleic acid molecule is a plasmid DNA.

92 (Withdrawn). The transfection composition of Claim 88, wherein said nucleic acid molecule is a small interference RNA (siRNA).

93 (Withdrawn). The transfection composition of Claim 88, wherein said nucleic acid molecule is an oligodeoxynucleotide (ODN).

94 (Withdrawn). The transfection composition of Claim 88, wherein the sphingoid-polyalkylamine conjugate forms lipid assemblies.

95 (Withdrawn). The composition of Claim 94, wherein the sphingoid-polyalkylamine conjugate forms vesicles and/or micelles.

96 (Withdrawn). The transfection composition of Claim 88, wherein the sphingoid backbone is selected from ceramide, dihydroceramide, phytoceramide, dihydrosphytoceramide, ceramine, dihydroceramine, phytoceramine, dihydrosphytoceramine.

97 (Withdrawn). The transfection composition of Claim 94, wherein said sphingoid is a ceramide.

98 (Withdrawn). The transfection composition of Claim 88, wherein said one or more polyalkylamine chains are independently selected from spermine, spermidine, a polyalkylamine analog or a combination thereof.

99 (Cancelled).

100 (Withdrawn). The transfection composition of Claim 88, wherein said sphingoid- polyalkylamine conjugate is N-palmitoyl D-erythro sphingosyl carbamoyl-spermine (CCS).

101-106 (Cancelled).